CTRI/2019/02/017873尚未招募2 期
A phase II trial to study efficacy, toxicity and immunomodulatory effect of Carctol-S in high grade serous epithelial ovarian cancer at first serological relapse.
Central Council for Research in Ayurvedic Sciences Ministry of AYUSH Government of India0 个研究点目标入组 0 人开始时间: 待定最近更新:
试验速览
- 阶段
- 2 期
- 状态
- 尚未招募
- 发起方
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
入选标准
- •1.Patients with high grade serous ovarian cancer who attained complete response to front line treatment and experienced first serological relapse.
- •2.European Cooperative Oncology Group (ECOG) Performance score is less than or equal to 1. 3.No evidence of disease on clinical examination. 4.No or minimal disease on CE-CT (abdomen, pelvis and thorax)
排除标准
- •1.Symptomatic patients.
- •2.Patients with evidence of disease on clinical examination.
- •3.Patients with evidence of significant disease on radiological
- •4.Patients who did not attain CR to frontline primary treatment.
- •5.Inability to follow up at regular intervals.
- •6.Inability to take oral medication
研究者
相似试验
招募中
2 期
To evaluate the impact of PET scan based radiotherapy planning for cervical cancer in Indian women.CTRI/2016/05/006924Department of Biotechnology Government of India60
进行中（未招募）
1 期
Trastuzumab and AUY922 in HER2-aberrant NSCLCAdvanced non-smallcell lung cancer with HER2 - overexpression or - amplification or - mutationMedDRA version: 17.1Level: PTClassification code 10061873Term: Non-small cell lung cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2011-005655-13-DEniversity of Cologne29
进行中（未招募）
1 期
A phase II trial to evaluate safety and efficacy of adding durvalumab (MEDI4736) to standard neoadjuvant radiochemotherapy and of adjuvant durvalumab +/- tremelimumab in locally advanced esophageal adenocarcinoma and to evaluate biomarkers predictive for response to immune checkpoint inhibitiolocally advanced esophageal adenocarcinomaMedDRA version: 20.0Level: LLTClassification code 10001173Term: Adenocarcinoma of esophagusSystem Organ Class: 100000004864EUCTR2018-003048-22-DEniversität zu Köln56
尚未招募
2 期
A phase II trial to evaluate safety and efficacy of combined trastuzumab and AUY922 in advanced non-small cell lung cancer (NSCLC) with HER2 - overexpression or -amplification or - mutation.HER2-overexpression or -amplification or -mutationC34Malignant neoplasm of bronchus and lungDRKS00003301niversität Köln29
进行中（未招募）
1 期
Treatment of advanced adenocarcinoma of the lungAdult patients with either firstly diagnosed or relapsed advanced adenocarcinoma of the lung harbouring ROS1 translocationMedDRA version: 17.1Level: LLTClassification code 10025032Term: Lung adenocarcinoma NOSSystem Organ Class: 100000004864EUCTR2013-002737-38-ATniversity of Cologne30